^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR L858R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) + Zolinza (vorinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer
Published date:
03/26/2021
Excerpt:
To address C797S resistance, a promising therapeutic avenue is combination therapy that targets both total EGFR and acquired mutations to increase drug efficacy. We showed that combining vorinostat, a histone deacetylase inhibitor (HDACi), with brigatinib, a TKI, enhanced antitumor effects in primary culture and cell lines of lung adenocarcinomas harboring EGFR L858R/T790M/C797S mutations (EGFR-3M).
DOI:
https://doi.org/10.1016/j.canlet.2021.03.022
